Floatz logo

Docetaxel

Cognitive/Functional Effects

University of California, San FranciscoSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Cognitive/Functional Effects cohort.

Asset / SponsorPhaseRating
Irinotecan
Alliance for Clinical Trials in Oncology
Phase 3BB
(+)-VINCRISTINE
Radiation Therapy Oncology Group
Phase 3BB
Sra-333
Alliance for Clinical Trials in Oncology
Phase 3BB
Namenda
Radiation Therapy Oncology Group
Phase 3BB
METHOTREXATE
OHSU Knight Cancer Institute
Phase 2BB

View all 22 →

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →